venetoclax + azacitidine + HAAG

This is a combination regimen consisting of three components: - **Venetoclax** is a potent, selective, oral small molecule inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein that helps cancer cells survive. By inhibiting BCL-2, venetoclax promotes apoptosis in malignant cells. - **Azacitidine** is a hypomethylating agent and nucleoside metabolic inhibitor that incorporates into DNA and RNA, leading to DNA hypomethylation and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. - **HAAG** refers to a chemotherapy regimen typically composed of homoharringtonine (HHT), cytarabine (Ara-C), aclarubicin, and granulocyte colony-stimulating factor (G-CSF). This multi-agent protocol combines antimetabolite activity (cytarabine), anthracycline antibiotic action (aclarubicin), protein synthesis inhibition (homoharringtonine), and myeloid growth stimulation (G-CSF). The combination aims to maximize anti-leukemic efficacy by targeting multiple pathways involved in acute myeloid leukemia cell survival and proliferation. Venetoclax plus azacitidine has demonstrated synergistic effects in AML treatment[1][6][10]. The addition of HAAG components may further intensify therapy for high-risk or refractory cases.